T2 Biosystems, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 16 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-06-06: Reporting owner Dhanda Rahul; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-06-06: Reporting owner Lapidus Stanley; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-06-06: Reporting owner McDonough John; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2017-06-06: Reporting owner McDonough John; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-06-06 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,000 0 owned after | $0.48 exercise price | 2017-06-08 | |
| 2017-06-06 | Lapidus Stanley Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 27,058 owned after | $1.16 exercise price | 2017-06-08 | |
| 2017-06-06 | McDonough John Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −16,806 0 owned after | $1.16 exercise price | 2017-06-08 | |
| 2017-06-06 | McDonough John Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −11,729 0 owned after | $1.16 exercise price | 2017-06-08 | |
| 2017-06-06 | McDonough John Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −21,465 106,025 owned after | $1.96 exercise price | 2017-06-08 | |
| 2017-06-06 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,000 14,647 owned after | $1.16 exercise price | 2017-06-08 | |
| 2017-06-06 | Cima Michael J. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 53,823 owned after | $1.96 exercise price | 2017-06-08 | |
| 2017-06-06 holding as of filing | Jones Adrian M Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 66,176 owned after | $8.92 exercise price | 2017-06-06 | |
| 2017-06-06 holding as of filing | GOLDMAN SACHS GROUP INC | GOLDMAN SACHS & CO. LLC 10% Owner | 10% Owner | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | Holding | 66,176 owned after | $8.92 exercise price | 2017-06-06 | |
| 2017-02-09 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | Harding David Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | McDonough John Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | Lynch Shawn Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | Gibbs Michael Terrence Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 | |
| 2017-02-09 | Spadoro Joanne Officer (Chief Operations Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,000 35,000 owned after | $5.67 exercise price | 2017-02-13 |